Pilz, Micha J.
Seyringer, Simone
Al-Naesan, Imad
King, Madeleine T.
Bottomley, Andrew
Norman, Richard
Schlosser, Lisa
Hell, Tobias
Gamper, Eva Maria
,
Funding for this research was provided by:
European Organisation for Research and Treatment of Cancer (#12/2016)
Article History
Accepted: 11 March 2024
First Online: 2 May 2024
Declarations
:
: This work was supported by an EORTC grant (#12/2016). The EORTC Quality of Life Group business model involves charges for commercial companies using EORTC instruments. Academic use of EORTC instruments is free of charge.
: The authors have no conflict of interest to declare.
: Ethical approval for this study was provided by the ethics board of the Medical University of Innsbruck as an amendment to the study AN 2015-0016.
: All patients provided written informed consent when participating in the original trials this retrospective analysis relies on. The original study protocols were developed in accordance with the Declaration of Helsinki, and ethical approval was sought at participating centres.
: Not applicable
: The results presented in this manuscript rely on the secondary analysis of trial data proprietary of the data contributor Boehringer Ingelheim. The authors of this article do not have the permission to make the original trial data or any other trial materials available for public use.
: Not applicable.
: Conceptualisation: Gamper E.M., King M.K., Norman R. Acquisition of data: Pilz M.J., Gamper E.M. Analysis and interpretation of data: Pilz M.J., Gamper E.M., Seyringer S., Al-Naesan I. Drafting of the manuscript: Pilz M.J., Seyringer S., Al-Naesan I., Gamper E.M. Critical revision of the manuscript: Bottomley A., King M.K., Norman R., Gamper E.M. Statistical analysis: Schlosser L., Hell T. Provision of study materials or patients: Bottomley A., King M.K., Norman R. Obtaining funding: Gamper E.M. Administrative, technical, or logistic support: King M.K., Norman R., Gamper E.M. Supervision: Gamper E.M. All authors have read and approved the manuscript.